抗发作药物和心血管事件在加拿大长度研究的老年人老龄化
Jimmy Li1,2, Nathan A Shlobin3, Roland D Thijs4,5,6
1Neurology Division, Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec, Canada.
JAMA neurology
|January 13, 2025
概括
会使新的心血管事件 (CVEs) 的风险增加两倍以上. 诱导酶的抗发作药物 (EIASM) 解释了这一关联的近三分之一,强调了药物选择的重要性.
科学领域:
- 心血管流行病学心血管流行病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 和心血管疾病 (CVD) 之间的联系尚不清楚.
- 患有的老年人可能患有心血管事件 (CVEs) 的风险更高.
研究的目的:
- 在老年人中确定和六年内新发的CVE之间的关联.
- 研究酶诱导抗发作药物 (EIASM) 和传统心血管风险因素的调解作用.
主要方法:
- 使用加拿大长度老龄化研究 (CLSA) 进行的前性队列研究,共有30097名参与者 (年龄在45-85岁之间).
- 长达6年的跟踪 (2015-2021年) 以确定新出现的CVE (中风,TIA,MI).
- 进行了后勤回归和调度分析,并对共变量进行了调整.
主要成果:
- 与新发性CVE的概率增加了2.20倍 (95% CI,1.48-3.27).
- 强烈的EIASM使用介导了和CVE相关性的24.6% (95% CI,6.5%-54.6%).
- 较弱的EIASM使用,弗雷明汉分数,PASE分数和腰比也显示了调解效应.
结论:
- 与老年人新心血管事件的风险增加有显著的关联.
- 诱导酶的抗发作药物在调解这种增加的风险方面发挥着重要作用.
- 关于抗发作药物的临床决定应考虑患者的心血管风险.
相关概念视频
Antiepileptic Drugs: Calcium Channel Blockers
301
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
301
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Potassium Channel Activators
142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
142
Antiepileptic Drugs: Sodium Channel Blockers
384
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
384
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
233
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
233


